ProQR Therapeutics N.V. reported second quarter 2026 financial results and provided a business update. The company announced positive Phase 1 target engagement data for AX-0810, establishing the first clinical validation of its Axiomer RNA editing platform through NTCP modulation. In June, ProQR closed an underwritten registered direct offering and concurrent private placement with Eli Lilly and Company, raising approximately $59.2 million in gross proceeds. This financing strengthened the balance sheet, bringing cash and cash equivalents to €117.1 million as of June 30, 2026, supporting operations through mid-2028. Net loss for the quarter was €8.7 million, or €0.08 per diluted share, compared to a net loss of €12.2 million in the prior year period. The company anticipates initial Phase 1 data for its next-generation candidate AX-0811 by year-end 2026 and plans to initiate an investigator-initiated trial for biliary atresia in China with data expected in the first half of 2027. ProQR Therapeutics is a clinical-stage biotechnology company developing transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform.

ProQR Therapeutics N.V. reported second quarter 2026 financial results and provided a business update. The company closed an underwritten registered direct offering of $50.0 million alongside a concurrent private placement with Eli Lilly for $9.2 million, totaling approximately $59.2 million in gross proceeds. This financing strengthened the balance sheet, ending Q2 2026 with €117.1 million in cash and cash equivalents, supporting operations through mid-2028. Net loss for the quarter was €8.7 million, or €0.08 per diluted share, compared to a net loss of €12.2 million, or €0.12 per diluted share, in the same period last year. R&D costs were €12.7 million and general and administrative costs were €4.9 million. Clinically, ProQR announced positive AX-0810 Phase 1 target engagement data establishing first clinical validation of its Axiomer RNA editing platform for NTCP modulation. The company also submitted a Clinical Trial Application to the EMA for AX-0811, with initial data expected by year-end 2026. ProQR Therapeutics is a clinical-stage biotechnology company developing transformative RNA therapies using its proprietary Axiomer RNA editing technology.

ProQR Therapeutics N.V. entered into an underwriting agreement on June 25, 2026, for a registered direct offering of 27,624,310 ordinary shares at $1.81 per share, expected to net approximately $46.5 million. Concurrently, the company entered into a share purchase agreement with Eli Lilly and Company for a private placement of 5,100,780 shares at the same price, generating approximately $9.2 million. ProQR Therapeutics N.V. is a biotechnology company focused on RNA-based therapeutics.

ProQR Therapeutics N.V. announced positive Phase 1 target engagement data for AX-0810 on June 25, 2026. This data provides the first clinical validation for the company's Axiomer RNA editing platform. ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based therapies.